FDA approves MSD’s Zinplava, antibody against Clostridium difficile infections

MSD announced that FDA has approved Zinplava (bezlotoxumab) Injection 25 mg/mL. The firm added it will make the drug available in first quarter 2017. Zinplava is indicated to reduce recurrence of Clostridium difficile infection (CDI) in patients 18 years of age or older who are being treated for this condition. The novel drug is not an antibacterial agent and should be used in conjunction with an antibacterial drug treatment of CDI. It is a monoclonal antibody that binds to C. difficile toxin B and neutralizes its effects (Source Business Wire)